Topics Include:

• The place for senolytics in the therapeutic landscape of retinal diseases
• The role of cellular senescence and Bcl-xL inhibition in diabetic macular edema (DME) and wet age-related macular degneration (AMD)
• Review of Phase 1 study data of senolytic candidate UBX1325 for the treatment of patients with DME and AMD

To join virtually or register for the in-person event, please email us at RSVP@unitybiotechnology.com*
^*Registration at the event is available on a first-come first-servered basis

Launch Zoom Webinar